Search results
Results from the WOW.Com Content Network
Mesoblast will also have exclusive access to Lonza's Cell Therapy facilities in Singapore for the manufacture of allogeneic cell therapies. [4] In May 2014, Mesoblast announced it would receive incentives from the Singapore Economic Development Board (EDB) for activities in Singapore related to manufacturing operations, product development, and ...
Cell therapy (also called cellular therapy, cell transplantation, or cytotherapy) is a therapy in which viable cells are injected, grafted or implanted into a patient in order to effectuate a medicinal effect, [1] for example, by transplanting T-cells capable of fighting cancer cells via cell-mediated immunity in the course of immunotherapy, or ...
Lineage is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. The company changed its name from BioTime Inc. to Lineage Cell Therapeutics less than one year following its appointment of a new CEO, Brian Culley, in August 2018 and completing a series of corporate transactions including the distribution of AgeX Therapeutics, the acquisition of ...
Also, "cell therapy" by producing five products for the treatment of skin and heart disease and knee arthritis, production of "peptide medications" using in the treatment of high-dose diseases such as Multiple sclerosis, blood diseases and cancer, "Research and development and processing of medicinal plants", in order to use domestic capacities ...
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. [1]
Axicabtagene ciloleucel (KTE-C19, ZUMA-3, YESCARTA) was an investigational therapy (for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)) in which a patient's T cells were genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias. [11]
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
Cellectis has developed CAR T-cell treatments for blood cancer. [11] Most CAR-T therapies under development as of 2017 involved taking T-cells from the person with cancer and applying gene therapy to those cells to activate them to attack the person's cancer; an autologous cell therapy approach.